-
Product Insights
NewAnal Cancer – Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
-
Product Insights
NewHigh-Grade Glioma – Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Product Insights
NewHypopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Hypopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end...
-
Product Insights
NewRectal Cancer – Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...
-
Product Insights
NewOropharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Oropharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which...
-
Product Insights
Aortic Stent Grafts Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Aortic Stent Grafts Pipeline Market Report Overview Aortic Stent grafts are used to reinforce a weak aorta to prevent ruptures. These grafts can be of allografts or synthetic materials. These are used to manage urinary incontinence and urinary retention in both men and women. The Aortic Stent Grafts pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMX-001 in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMX-001 in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMX-001 in Rectal Cancer Drug Details: BMX-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMX-001 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMX-001 in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMX-001 in Hypopharyngeal Cancer Drug Details: BMX-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMX-001 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMX-001 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMX-001 in Laryngeal Cancer Drug Details: BMX-001 is under development for the...